Ruxolitinib therapy does not influence virus load in LCMV infected cytotoxicity-deficient mice. (A) Viral titers in the liver from control (B6) and Prf1^−/− mice and (B) of control (B6) and Rab27a^−/− mice nontreated or treated with ruxolitinib for 14 days and analyzed at the indicated points. Data (mean ± SEM) are representative of 3 independent experiments with at least 3 mice in each group. ns, nonsignificant.